mango
Senior Member
- Messages
- 905
http://me-forskning.no/oppdatering-fra-haukeland-om-rituxme-studien/
Translated by Google:
Translated by Google:
Update from Haukeland about RituxME study
The following is an update from studiekordinator Kari Sørland
Update, RituxME study
Multi-center study RituxME completed enrollment of all 152 participants in September 2015. By the summer holidays, all patients in Bergen, Trondheim, Notodden and Oslo have completed their course of treatment, and study center in Tromsø provides final treatment in September.
As known RituxME a double blind study, meaning that neither the patient or treating know about the individual patient is receiving active medication or placebo. Blinding is maintained until the last participant has finished one year of follow-up after stopping treatment, and we will therefore be able to break the code in September 2017. The results of RituxME study will be published in a scientific paper during 2018.
Research biobank at Haukeland University Hospital has been expanded with blood tests before treatment from all participants, and together with samples from previous studies and the ongoing cyclofosfamidstudien, these blood samples a unique material for research on disease mechanisms and a possible biomarker.
There is currently a lot of activity in the laboratory at Haukeland, and it is partnered with several national and international institutions on study on including autoantibodies, immune signatures, cell metabolism and genetics, where material from the biobank included. We continue to take samples to the Biobank at fixed times their studies until the last patient has completed follow-up.
Kari Sørland
Programme coordinator